Research Papers:
The long noncoding RNA NONHSAG026900 predicts prognosis as a favorable biomarker in patients with diffuse large Bcell lymphoma
PDF | Full Text | How to cite
Shuangtao Zhao1,*, Shuangsang Fang2,*, Yanhua Liu3,4,5,*, Xixi Li3,6, Shengyou Liao2, Jinwen Chen2, Jingjia Liu2, Lianhe Zhao2, Hui Li2, Wei Zhou3,4,5, Wenzhi Shen3,4,5, Xiaoli Dong3,4,5, Rong Xiang3,4,5, Luhua Wang1, Yi Zhao2
1Department of Radiation Oncology, National Cancer Center/Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China
2The Key Laboratory of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, Beijing, China
3The School of Medicine, Nankai University, Tianjin, China
4The Collaborative Innovation Center for Biotherapy, Nankai University, Tianjin, China
5The Tianjin Key Laboratory of Tumor Microenvironment and Neurovascular Regulation, Tianjin, China
6Department of Pathology, Nankai University, Tianjin, China
*Co-first author
Correspondence to:
Rong Xiang, email: rxiang@nankai.edu.cn
Luhua Wang, email: wlhwq@yahoo.com
Yi Zhao, email: biozy@ict.ac.cn
Keywords: diffuse large B-cell lymphoma, long non-coding RNA, NONHSAG026900, prognosis, biomarker
Received: January 17, 2017 Accepted: February 24, 2017 Published: March 13, 2017
ABSTRACT
Long non-coding RNAs are known to be involved in cancer progression, but their biological functions and prognostic values are still largely unexplored in diffuse large B-cell lymphoma. In this study, long non-coding RNAs expression was characterized in 1,403 samples including normal and diffuse large B-cell lymphoma by repurposing 7 microarray datasets. Compared with any stage of normal B cells, NONHSAG026900 expression was significantly decreased in tumor samples. And in germinal center B-cell subtype, the significantly higher expression of NONHSAG026900 indicated it was a favorable prognosis biomarker. Then the prognostic power of NONHSAG026900 was validated with another independent dataset and NONHSAG026900 improved the predictive power of International Prognostic Index as an independent factor. Moreover, functional prediction and validation demonstrated that NONHSAG026900 could inhibit cell cycle activity to restrain tumor proliferation. These findings identified NONHSAG026900 as a novel prognostic biomarker and offered a new therapeutic target for diffuse large B-cell lymphoma patients.